Researchers at the Fralin Biomedical Research Institute at Virginia Tech have created an experimental oral medication that protected mice from otherwise lethal doses of radiation while still allowing radiation therapy to destroy cancer cells. This finding, described in a report published by Medical Xpress, could lead to better cancer treatments and stronger preparedness for radiological emergencies, though human testing has not yet begun.

Key takeaways

  • An experimental oral therapy shielded mice from high doses of radiation that would normally be fatal.
  • The therapy did not interfere with radiation’s ability to kill cancer cells in the same animals.
  • Researchers hope the approach could improve human cancer treatment and help in radiological disasters.
  • Human studies are still needed to confirm safety and effectiveness in people.

How the therapy works

The oral therapy is designed to protect healthy tissues from radiation damage while leaving cancer cells vulnerable. According to the original report from Medical Xpress, the compound works by activating pathways in normal cells that help them withstand radiation stress. Cancer cells, however, lack these pathways or do not respond to the compound, so radiation can still kill them. This selectivity is a key feature of the approach.

Study details and findings

In the laboratory study, mice received a single dose of the oral therapy before being exposed to levels of radiation that would normally be lethal. All treated mice survived, while untreated mice did not. In separate experiments, mice with tumors were given the same therapy plus radiation. The tumors shrank at the same rate as tumors in mice that received radiation alone, indicating that the therapy did not protect cancer cells.

Potential applications

The researchers see two main uses for the therapy. First, it could be given to cancer patients before radiation therapy to reduce damage to healthy organs such as the lungs, gut, and bone marrow. Second, it could be used in radiological emergencies, such as nuclear accidents or terrorist attacks, to protect first responders or the public from acute radiation syndrome. The oral form makes it practical for large-scale distribution.

What this means for humans

The results are promising, but the therapy has only been tested in mice. The next steps involve safety studies in larger animals and eventually clinical trials in humans. Many experimental treatments that work in mice do not work in people, so caution is warranted. The researchers are working to move the therapy toward human testing, but no timeline has been announced.

Frequently Asked Questions

How does the oral therapy protect against radiation?

The therapy activates protective pathways in healthy cells, making them more resistant to radiation damage. It does not activate those pathways in cancer cells, so they remain sensitive to radiation therapy.

Will the therapy interfere with cancer treatment?

In the mouse study, the therapy did not reduce the effectiveness of radiation against tumors. The tumors regressed similarly whether or not the mice received the oral therapy. This suggests it may spare cancer treatment while protecting healthy tissue.

When might this therapy be available for humans?

Human testing has not yet started. The therapy must first undergo safety studies in animals, then clinical trials to prove it is safe and effective in people. This process typically takes several years. The researchers are optimistic but have not given a specific timeline.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.